BioSpace News Archive

FDA

Merck’s Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia

Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are life-threatening hospital-related pulmonary infections that can particularly impact patients who are already dealing with severe underlying medical conditions.

June 4, 2019
·
3 min read
·
Alex Keown
Drug Development

ASCO Updates: RemeGen, Genentech, Johnson & Johnson, Bristol-Myers Squibb and Bayer

As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.

June 4, 2019
·
4 min read
·
Mark Terry
With Lynparza and Imfinzi, AstraZeneca Redefines Itself in Oncology

AstraZeneca underwent a restructuring earlier this year with an increased focus on oncology.

June 4, 2019
·
3 min read
·
Alex Keown
BioMidwest

Kite Pharma Presents Updated Safety Data for Hard-to-Treat Blood Cancers

At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.

June 4, 2019
·
4 min read
·
Alex Keown
BioCapital

Your Feedback Matters! Work-Life Balance

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your if you have ‘work-life balance’ with your job.

June 4, 2019
·
1 min read
·
BioSpace Staff
Biotech Bay

Continued Dosing of Peanut Allergy Therapy Leads to Greater Tolerance, Trial Data Shows

The add-on data showed that longer treatment with AR101 provided higher tolerance levels to peanut protein.

June 4, 2019
·
2 min read
·
Alex Keown
Pharm Country

Study Shows Keytruda’s Promise in Treating Head and Neck Cancer

Patients were given Merck’s Keytruda (pembrolizumab) in combination with platinum chemotherapy, Keytruda by itself or chemotherapy by itself. The trial results found that the combination extended survival, and immunotherapy alone also worked well for some patients.

June 4, 2019
·
2 min read
·
Mark Terry
Opioid analgesics increase the risk of pneumonia among persons with Alzheimer’s disease

Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer’s disease, a recent study from the University of Eastern Finland shows.

June 4, 2019
·
2 min read
Drug Development

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

June 4, 2019
·
4 min read
Deals

Yukin Therapeutics raises €3.3 million to develop new cancer treatments

Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.

June 4, 2019
·
4 min read